Fig. 2From: Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomesBox plots with dot plots, showing the number of red headache days/month at baseline (month 2) and 3, 6 and 9 months after treatment initiation (respectively months 5, 8 and 11)Back to article page